Attenuation of clinical and immunological outcomes during SARS‐CoV‐2 infection by ivermectin

Attenuation of clinical and immunological outcomes during SARS‐CoV‐2 infection by ivermectin

Abstract The devastating pandemic due to SARS‐CoV‐2 and the emergence of antigenic variants that jeopardize the efficacy of current vaccines create an urgent need for a comprehensive understanding of the pathophysiology of COVID‐19, including the contribution of inflammation to disease. It also warr...

Full description

Bibliographic Details
Main Authors: Guilherme Dias deMelo, Françoise Lazarini, Florence Larrous, Lena Feige, Etienne Kornobis, Sylvain Levallois, Agnès Marchio, Lauriane Kergoat, David Hardy, Thomas Cokelaer, Pascal Pineau, Marc Lecuit, Pierre‐Marie Lledo, Jean‐Pierre Changeux, Hervé Bourhy
Format: Article
Language:English
Published: Wiley 2021-08-01
Series:EMBO Molecular Medicine
Subjects:
coronavirus
inflammation
ivermectin
SARS‐CoV‐2
viral infections
Online Access:https://doi.org/10.15252/emmm.202114122

Internet

https://doi.org/10.15252/emmm.202114122

Similar Items